Current Lawsuits: Hernia Mesh | Depuy Pinnacle Hip | Stryker Hip | Other Metal Hip | Taxotere | Talcum Powder
Personal Injury Lawyer -

Free case review

facebook logo google+ logo twitter logo youtube logo

Testosterone Replacement Therapy lawsuit News and Updates

• January 23, 2018

Eli lilly & Co. annouce global settlement in testosterone replacement therapy lawsuit

Right before the start of the first bellwether trial scheduled in the Testosterone MDL, the manufacturer, Eli Lilly & Co., announced that it has reached a global settlement in all cases filed against it in the Testosterone Replacement Therapy Products Liability Litigation. About 6000 cases were pending against Eli Lilly,

Eli Lilly & Co was facing claims that it failed to warn that its testosterone replacement therapy drug Axiron, could cause potentially deadly heart attacks, strokes and blood clots. Testosterone treatments are indicated for men with hypogonadism, a condition in which men have low testosterone levels due to defect, disease or injury. However, many men took it off label for “Low T”.

The manufacturer advised the Court that it had entered into a ‘memorandum of understanding’ to resolve all pending litigation. As a result, two upcoming trial dates involving Axiron were cancelled. The trials involved the case of Tracy Garner, who claimed that using Axiron caused him to suffer a heart attack, and the case of John DeBroka Jr., who said he developed deep vein thrombosis, a blood clot in the deep veins, after taking Axiron.

The terms of the settlement were not outlined in the court documents. Previous verdicts of $290 million against drug maker AbbVie for injuries caused by Testosterone, may have prompted Eli Lilly to settle.

Talk with aN Attorney now!

• June 30, 2017

Illinois Court Selects Two Bellwether Cases in Testosterone Replacement Trial

The U.S. District Court for the Northern District of Illinois has selected two cases that will represent more than 6000 others in a Multi-District Litigation (MDL) case against testosterone replacement drug manufacturer Eli Lilly. These “bellwether trials” typically set precedents for future rulings in similar cases.

Tracy Garner, plaintiff in one of the bellwether cases, suffered a myocardial infarction; John Debroka, plaintiff in the other bellwether case, suffered deep vein thrombosis. Both plaintiffs – along with the plaintiffs in the other 6000 cases – allege that topical testosterone replacement drugs, such as Eli Lilly’s Axiron, are to blame for their health crises.

Other major drug manufacturers that have released topical testosterone products include AbbVie, Actavis, Auxilium Pharmaceuticals, Endo Pharmaceuticals, Pharmacia, and Pfizer.

The central issue in the cases is whether topical testosterone treatments can cause such serious medical conditions as deep vein thrombosis, heart attacks, pulmonary embolisms, and strokes.

Testosterone therapy drugs, whether topical or oral, are prescribed for a range of symptoms, including decreased muscle mass, depleted energy, and reduction in libido.

The U.S. Food and Drug Administration (FDA) has been investigating topical testosterone drugs since 2014, and in 2015 issued a formal warning about the products.

If you or a loved one has suffered health problems as a result of using topical testosterone replacement drugs – or from any other drug that you believe to be a health risk – contact your doctor.

Then, contact The consultation is always free, and we will always advocate for your health.

Talk with aN Attorney now!   

• June 23, 2017

Judge Selects First Two Cases in Eli Lilly Testosterone Suit

A federal judge in Illinois has selected the first two cases to be tried in a Multi-District Litigation (MDL) case about the testosterone replacement drugs manufactured by pharmaceutical corporation Eli Lilly.

The cases of John DeBroka, Jr., and Tracy Garner will be the first to be heard in the trial concerning Eli Lilly’s Axiron testosterone therapy drug. Garner alleges that Axiron caused his heart attack; DeBroka alleges that Axiron caused his deep vein thrombosis.

The cases will be heard in January and March of 2018.

The MDL case consolidates nearly 6000 testosterone therapy cases. About two-thirds of those cases have been filed against AbbVie, a drug company that manufactures a testosterone replacement drug called AndroGel that can be applied topically.

Plaintiffs in all of the cases allege that the drug manufacturers marketed their products to men who did not actually need it, and that the drugs have caused serious and sometimes fatal health problems, such as heart attacks and strokes. At issue is whether testosterone therapy drugs cause the blood to clot.

A case against AbbVie about AndroGel ended in a mistrial, but will be recalled for trial in September.

Numerous other cases concerning the dangers of testosterone replacement drugs are currently working their way through the court system.

If you’ve had serious health problems as a result of using testosterone therapy drugs, contact the expert attorneys at We will advocate for your health.

Contact to learn how we can help you.

Talk with aN Attorney now!

Free Case Review